Celgene Corp - Company Profile
Powered by
All the data and insights you need on Celgene Corp in one report.
- Save hours of research time and resources with
our up-to-date Celgene Corp Strategy Report
- Understand Celgene Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Celgene Corp Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Celgene Corp Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 03 Oct 2019 | Lorem |
Bellicum’s Phase I/II six-patient data for CAR-T BPX-601 in pancreatic cancer expected at ESMO IO 2019 or ASCO GI 2020, exec says | 03 Jul 2019 | Manasi Vaidya |
Servier plans to present Onivyde 1L combination pancreatic cancer data at ESMO GI, exec says | 06 Jun 2019 | Manasi Vaidya |
Aadi enrolls nine patients in nanoparticle albumin-bound mTOR inhibitor Phase I PAH study, likely to assess one more dose, source says | 24 May 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer